A Phase 1, Randomized, Double-Blind, Third-Party Open, Placebo-Controlled, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability, Immunogenicity, and Pharmacodynamics Following Intravenous Dose of PF-07275315 in Chinese Healthy Adult Participants
Latest Information Update: 19 May 2025
At a glance
- Drugs PF-07275315 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
Most Recent Events
- 11 May 2025 Planned End Date changed from 16 Aug 2025 to 17 Jul 2025.
- 11 May 2025 Planned primary completion date changed from 16 Aug 2025 to 17 Jul 2025.
- 11 May 2025 Status changed from not yet recruiting to active, no longer recruiting.